111 related articles for article (PubMed ID: 1689427)
1. Effects of amrinone and enoximone on the subclasses of cyclic AMP phosphodiesterase from human heart and kidney.
Masuoka H; Ito M; Nakano T; Naka M; Tanaka T
J Cardiovasc Pharmacol; 1990 Feb; 15(2):302-7. PubMed ID: 1689427
[TBL] [Abstract][Full Text] [Related]
2. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs.
Harrison SA; Reifsnyder DH; Gallis B; Cadd GG; Beavo JA
Mol Pharmacol; 1986 May; 29(5):506-14. PubMed ID: 3010079
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds.
de Cheffoy de Courcelles D; de Loore K; Freyne E; Janssen PA
J Pharmacol Exp Ther; 1992 Oct; 263(1):6-14. PubMed ID: 1328613
[TBL] [Abstract][Full Text] [Related]
4. Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism.
Ahn HS; Eardley D; Watkins R; Prioli N
Biochem Pharmacol; 1986 Apr; 35(7):1113-21. PubMed ID: 2421728
[TBL] [Abstract][Full Text] [Related]
5. Differential inhibition of cardiac cyclic nucleotide phosphodiesterase isozymes by cardiotonic drugs.
Harrison SA; Chang ML; Beavo JA
Circulation; 1986 Mar; 73(3 Pt 2):III109-16. PubMed ID: 3002661
[TBL] [Abstract][Full Text] [Related]
6. Subclasses of cyclic AMP phosphodiesterase in cardiac muscle.
Weishaar RE; Kobylarz-Singer DC; Kaplan HR
J Mol Cell Cardiol; 1987 Oct; 19(10):1025-36. PubMed ID: 2830402
[TBL] [Abstract][Full Text] [Related]
7. Two isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent.
Masuoka H; Ito M; Sugioka M; Kozeki H; Konishi T; Tanaka T; Nakano T
Biochem Biophys Res Commun; 1993 Jan; 190(2):412-7. PubMed ID: 8381275
[TBL] [Abstract][Full Text] [Related]
8. Myocardial cyclic AMP augmentation with high-dose PDEIII inhibitor in terminal warm blood cardioplegia.
Ko Y; Morita K; Nagahori R; Kinouchi K; Shinohara G; Kagawa H; Hashimoto K
Ann Thorac Cardiovasc Surg; 2009 Oct; 15(5):311-7. PubMed ID: 19901885
[TBL] [Abstract][Full Text] [Related]
9. Cyclic nucleotide phosphodiesterases from frog atrial fibers: isolation and drug sensitivities.
Lugnier C; Gauthier C; Le Bec A; Soustre H
Am J Physiol; 1992 Mar; 262(3 Pt 2):H654-60. PubMed ID: 1373036
[TBL] [Abstract][Full Text] [Related]
10. Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue.
Price B; Pyne NJ; Houslay MD
Biochem Pharmacol; 1987 Dec; 36(23):4047-54. PubMed ID: 2825712
[TBL] [Abstract][Full Text] [Related]
11. Subcellular distribution of high-affinity type IV cyclic AMP phosphodiesterase activity in rabbit ventricular myocardium: relations to the effects of cardiotonic drugs.
Kithas PA; Artman M; Thompson WJ; Strada SJ
Circ Res; 1988 Apr; 62(4):782-9. PubMed ID: 2832097
[TBL] [Abstract][Full Text] [Related]
12. Dilatory effects of phosphodiesterase inhibitors on human hand veins in vivo.
Grossmann M; Braune J; Ebert U; Kirch W
Eur J Clin Pharmacol; 1998 Mar; 54(1):35-9. PubMed ID: 9591928
[TBL] [Abstract][Full Text] [Related]
13. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility.
Weishaar RE; Kobylarz-Singer DC; Steffen RP; Kaplan HR
Circ Res; 1987 Oct; 61(4):539-47. PubMed ID: 2820608
[TBL] [Abstract][Full Text] [Related]
14. Bemoradan--a novel inhibitor of the rolipram-insensitive cyclic AMP phosphodiesterase from canine heart tissue.
Moore JB; Combs DW; Tobia AJ
Biochem Pharmacol; 1991 Jul; 42(3):679-83. PubMed ID: 1650219
[TBL] [Abstract][Full Text] [Related]
15. Differential sensitivity to cardiotonic drugs of cyclic AMP phosphodiesterases isolated from canine ventricular and sinoatrial-enriched tissues.
Komas N; Lugnier C; Le Bec A; Serradeil-Le Gal C; Barthélémy G; Stoclet JC
J Cardiovasc Pharmacol; 1989 Aug; 14(2):213-20. PubMed ID: 2476593
[TBL] [Abstract][Full Text] [Related]
16. Cyclic AMP phosphodiesterase from human heart and drug action.
Tanaka T; Masuoka H; Ito M; Nakano T; Naka M; Hidaka H
Adv Second Messenger Phosphoprotein Res; 1992; 25():373-81. PubMed ID: 1313268
[No Abstract] [Full Text] [Related]
17. Comparison of enoximone, amrinone, or levosimendan enriched St. Thomas' hospital cardioplegic solutions used for myocardial preservation in isolated guinea pig hearts.
Köksal C; Süzer O; Bozkurt AK; Köseoğlu S
Acta Medica (Hradec Kralove); 2002; 45(3):93-7. PubMed ID: 12515045
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of cyclic AMP phosphodiesterase from various human tissues by milrinone, a potent cardiac bipyridine.
Ito M; Tanaka T; Saitoh M; Masuoka H; Nakano T; Hidaka H
Biochem Pharmacol; 1988 May; 37(10):2041-4. PubMed ID: 2837222
[TBL] [Abstract][Full Text] [Related]
19. Purification and characterization of guanosine 3',5'-monophosphate-inhibited low K(m) adenosine 3',5'-monophosphate phosphodiesterase from human placental cytosolic fractions.
LeBon TR; Kasuya J; Paxton RJ; Belfrage P; Hockman S; Manganiello VC; Fujita Yamaguchi Y
Endocrinology; 1992 Jun; 130(6):3265-74. PubMed ID: 1317779
[TBL] [Abstract][Full Text] [Related]
20. Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle.
Silver PJ; Hamel LT; Perrone MH; Bentley RG; Bushover CR; Evans DB
Eur J Pharmacol; 1988 May; 150(1-2):85-94. PubMed ID: 2841146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
